News

Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

ROCKVILLE, Md., May 08, 2017 (GLOBE NEWSWIRE) — Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it will present preliminary data from the Phase IIa study of RX-3117 in advanced and metastatic bladder cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, which is being held June 2-6 in Chicago, Illinois.

2017-06-21T10:37:54+00:00